Exploring the Case for Investment in Hepatitis Scale Up in South Africa, February 2018
In an article published in Health Policy and Planning, three Pharos staff and other collaborators from South Africa, Harvard, and Imperial College, and the Center for Disease Analysis present one of the first comprehensive investment cases for hepatitis scale-up in low and middle- income countries. In South Africa, Pharos supported the development of a five-year national strategy for hepatitis B and C, covering activities including hepatitis B birth dose vaccination, prevention of vertical transmission, treatment of hepatitis B, and treatment of hepatitis C with the new generation of highly-effective cures. The investment case synthesizes the expected cost, health impact, cost-effectiveness, and budget impact of this package of interventions. The paper finds that scale up of hepatitis investments could be both affordable and represent good value for money for South Africa, while averting thousands of new infections, deaths, and cases of advanced liver disease